Sign in
CompletedPhase 2

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

Key facts

Who runs it
Clear Scientific, Inc.
Where
Glendale, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
34 people enrolled
Started
5 Feb 2026
Ended
29 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Methamphetamine
  • Sterile Saline
  • CS-1103
Record updated
10 November 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Other criteria

  • Major Inclusion Criteria:
  • Healthy participants aged 18 to 55 years, inclusive
  • Meets DSM-5 criteria for methamphetamine use disorder
  • Not seeking treatment for methamphetamine use disorder
  • Primary route of methamphetamine self-administration must be intravenous or smoking
  • Able to abstain from methamphetamine without experiencing severe withdrawal
  • A body mass index between 18 to 30 kg/m2, inclusive and a minimum body weight of 56 kg
  • Females must not be lactating and must have a negative pregnancy test during screening and admission; Major Exclusion Criteria:
  • Estimated glomerular filtration rate <60 mL/min/1.73 m2
  • History of cardiovascular disease
  • Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines
  • History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation

Where in United States

  • California Clinical Trials Medical GroupGlendale, United States

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Participants receive methamphetamine HCl (30 mg) followed by placebo (saline).

    Treatment: Methamphetamine and Sterile Saline

  • ActiveExisting treatment, for comparison

    Participants receive methamphetamine HCl (30 mg) followed by one of four doses of CS-1103

    Treatment: Methamphetamine and CS-1103

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine
Record updated
10 November 2026